Closely-held cell therapy manufacturer, Cellares, appointed Ezekiel Emanuel, M.D. and Ph.D., to its board of advisors. Dr. Emanuel is a bioethicist and currently vice provost for global initiatives, the Diane and Robert Levy university professorship, and co-director of the Healthcare Transformation Institute at the University of Pennsylvania.
Dr. Emanuel is a leading voice on public health issues, especially overcoming barriers that prevent patients from getting the care they need. His guidance will be key as Cellares advances the Cell Shuttle, its end-to-end solution for scalable cell therapy manufacturing.
In a statement, Dr. Emanuel said that throughout health care, new technology has meant rising costs, not lower. Advances in cell therapy, while life savings, are no different: they have consistently meant higher costs.
“What attracts me to Cellares is that the company is changing the paradigm not just for cell therapies, but for all of health care. It is demonstrating that technological innovation can lower health care costs. Their innovation will change all our assumptions on the limitations in drugs, biologics, and cell therapies,” he added.
Fabian Gerlinghaus, CEO and co-founder of Cellares, said throughout his career, including as a policy advisor to multiple presidential administrations, Dr. Emanuel has been dedicated to improving access to healthcare. “And at Cellares, we’re perfectly aligned with this pressing need as we work to make life-saving therapies more accessible to patients,” Mr. Gerlinghaus said.